Severe acute respiratory syndrome

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Retrieved on: 
Tuesday, June 15, 2021
Sarbecovirus, Respiratory diseases, Medical specialties, Animal diseases, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, TLR2

The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.

Key Points: 
  • The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
  • The milestone-based financing round was jointly led by Australian life science investors Brandon Capital Partners and Minderoo Foundation, with co-investment from Uniseed.
  • We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19, said Chris Smith, Ph.D., Chairman of ENA Respiratory.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Asahi Kasei and Nara Medical University Confirm 226 nm UVC LED Efficacy Against SARS-CoV-2 and Verify Reduced Effect on Animal Skin Cells

Retrieved on: 
Monday, June 14, 2021
Other Consumer, Other Health, Pets, Other Science, Pharmaceutical, Research, Other Technology, Infectious diseases, Hardware, Consumer, Science, Consumer electronics, Other Natural Resources, Technology, General Health, Biotechnology, Agriculture, Natural Resources, Health, Electromagnetic radiation, Ultraviolet radiation, Electrodynamics, Radiation, LED lamps, Display technology, Light-emitting diode, Signage, Ultraviolet, COVID-19, Severe acute respiratory syndrome, Germicidal lamp, the Tests, Asahi Kasei, Crystal IS, THE TESTS, ASAHI KASEI, CRYSTAL IS

Asahi Kasei announces the results of joint research with Nara Medical University regarding the efficacy of 226 nm ultraviolet-C (UVC) LEDs in the inactivation of the coronavirus (SARS-CoV-2) that causes COVID-19, and its effects on animal skin cells.

Key Points: 
  • Asahi Kasei announces the results of joint research with Nara Medical University regarding the efficacy of 226 nm ultraviolet-C (UVC) LEDs in the inactivation of the coronavirus (SARS-CoV-2) that causes COVID-19, and its effects on animal skin cells.
  • This is the first study in the world conducted with LEDs of this wavelength, and the results confirm that the 226 nm UVC LEDs are able to quickly inactivate SARS-CoV-2 while having significantly less effect on animal skin cells than 270 nm UVC LEDs.
  • An additional experiment was conducted on mouse skin cells to estimate the damage that 226 nm UVC LED light has on animal skin compared with 270 nm light.
  • The above results indicate that 226 nm UVC LEDs can quickly inactivate SARS-CoV-2 while having significantly less effect on animal skin cells compared to the current generation of 270 nm UVC LEDs for disinfection.

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device

Retrieved on: 
Friday, June 11, 2021
Biotechnology, FDA, Health, Medical devices, Medicine, Branches of biology, Clinical medicine, Medical tests, Immunologic tests, Molecular biology, Clinical Laboratory Improvement Amendments, Healthcare in the United States, Surround optical-fiber immunoassay, COVID-19, Severe acute respiratory syndrome, Quidel Corporation

Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.

Key Points: 
  • Sofia Q features a sleek, miniaturized design that reads the same Sofia SARS Antigen FIA tests as Sofia and Sofia 2 - with equal accuracy.
  • Sales of Sofia Q device will initially be limited to use with the Sofia SARS Antigen FIA in the CLIA and CLIA-waived professional segments.
  • In addition to the Sofia Q, Quidel offers other rapid diagnostic instrumented systems, including Sofia 2, and Sofia.
  • Quidels Sofia assays for rapid antigen COVID-19 diagnosis include Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA.

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

Retrieved on: 
Friday, June 11, 2021
Oncology, Health, Medical devices, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medicine, Branches of biology, Clinical medicine, Medical tests, Biotechnology, Molecular biology, Immunologic tests, Chromatography, Rapid antigen test, Lateral flow test, Severe acute respiratory syndrome, Polymerase chain reaction

Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.

Key Points: 
  • Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others.
  • The clinical data for Avactas AffiDX SARS-CoV-2 antigen lateral flow test reported 20 April 2021, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
  • The product registration by a Competent Authority in the EU allows the Company to sell the product in the EU for professional use.
  • Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented: We are delighted to receive confirmation of the registration of the AffiDX SARS-CoV-2 antigen test in the EU.

NYU Langone Health to Co-Lead NIH-funded Effort to Understand Long-term Effects of SARS-CoV-2 Infection

Retrieved on: 
Thursday, June 10, 2021
Coronaviridae, Sarbecovirus, Respiratory diseases, Animal diseases, COVID-19, Long Covid, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, PASC, NYU Langone Health

NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.

Key Points: 
  • NEW YORK, June 10, 2021 /PRNewswire/ -- NYU Langone Health has been selected as the Clinical Science Core (CSC) for the National Institutes of Health's PASC (Post-Acute Sequelae of SARS-CoV-2 Infection) Initiative.
  • Congress provided $1.15 billion in funding over four years for NIH to support research into the prolonged health consequences of SARS-CoV-2 infection in December of 2020.
  • How many people continue to have symptoms of COVID-19, or even develop new symptoms, after acute SARS-CoV-2 infection?
  • The PASC CSC at NYU Langone Health (NIH funding no.

New England Biolabs®, Inc. Launches Primer Monitor Tool for Tracking SARS-CoV-2 Variants That May Impact Primers Used in Diagnostic Assays

Retrieved on: 
Thursday, June 10, 2021
Natural sciences, Articles, Life sciences, Laboratory techniques, Molecular biology, Sarbecovirus, Polymerase chain reaction, Zoonoses, New England Biolabs, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Real-time polymerase chain reaction

The Primer Monitor Tool , which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.

Key Points: 
  • The Primer Monitor Tool , which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.
  • As the SARS-CoV-2 virus has continued to spread and mutate, concerns have been raised about the effectiveness of current diagnostic tests to detect new strains of the virus.
  • "The tool is pre-loaded with commonly used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (currently v3).
  • NEB and NEW ENGLAND BIOLABS are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-inc-launches...

Xlife Sciences AG: Breakthrough in Drug Development

Retrieved on: 
Thursday, June 10, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Health, Clinical medicine, Medicine, Pandemics, Epidemiology, Virus, Zoonoses, Severe acute respiratory syndrome

Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses.

Key Points: 
  • Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses.
  • About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry.
  • Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.
  • Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.

Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Wednesday, June 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Respiratory diseases, Animal diseases, Health, Antiviral drug, Biocides, COVID-19, Severe acute respiratory syndrome

No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.

Key Points: 
  • No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.
  • SLV213 has demonstrated activity against SARS-CoV-2 in vitro and in vivo and completed a Phase 1 clinical trial for safety.
  • As an oral antiviral, SLV213 has the potential to fill a critical gap in the treatment landscape for COVID-19.
  • Selva previously reported that SLV213 successfully completed a Phase 1 ascending oral dose clinical trial in healthy subjects.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Health, Clinical medicine, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome, Breakthrough infection, MedRxiv

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • The study was released in preprint via medRXiv.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on: 
Tuesday, June 8, 2021
Medical specialties, Health, Clinical medicine, Occupational safety and health, Atypical pneumonias, COVID-19, Public health, Zoonoses, Severe acute respiratory syndrome, Breakthrough infection, MedRxiv

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • The study was released in preprint via medRXiv.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.